Skip to main content

This job has expired

You will need to login before you can apply for a job.

Senior Scientist, Oligonucleotide Process Sciences

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
Aug 23, 2024
View more categoriesView less categories

Job Details

Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

How you will Achieve More with Intellia:

We would be thrilled to welcome a new Sr. Scientist – Oligonucleotide Process Sciences to our growing team and company. These are very exciting times of growth for Intellia and if you are highly motivated, proactive, and detail-oriented with an operational vision and enjoy working in cross-functional teams, this might be the right position for you.

This is a hands-on role in Oligonucleotide (sgRNA) process development for CRISPR/Cas 9 with the opportunity to support Intellia’s development pipeline for generating curative genome editing therapies. If you are a problem-solver with curiosity to learn about synthetic oligonucleotides and genome editing or you already have a technical background in oligonucleotide synthesis and purification, this is the role for you. Working in a new and engaged team within Technical Operations you would be supporting various activities including:

  • Contribute to develop a robust upstream and downstream sgRNA manufacturing process for Intellia therapeutics. Prepare and perform solid phase oligonucleotide syntheses (scale-down model) and purificationsas well as associated in-process and final analytics as needed.

  • Review manufacturing data to inform, plan, and execute process development
    activities.

  • Utilize knowledge gained from internal work and external CDMO activities to inform best path forward toward process development activities. Accordingly, plan and execute process development studies (upstream/downstream) with the objective tointroduce process improvements into the GMP manufacturing of sgRNA. Support associated techtransfers.

  • Document internal process development activities/ work-flow and results, generate easily readable report for completed projects for future reference.

  • Act as SME to maintain instrumentation, create/document laboratory processes as well as train new and existing group member where appropriate (generate SOP/Text instruction etc. as needed).

  • Train and transfer testing and optimization of downstream oligonucleotide processing including chromatographic purification methods to new or existing team member.

  • Act as technical resource and author/review technical documentation such as SOPs, method documents, training documents, batch records and reports.

  • Access the literature, guidance for industry, databases, and technical documents to contributeto regulatory authoring and PD strategy as needed.

  • Adopt conditions from external manufacturers and internal research for feasibility assessments. Work cross-functionally with representatives of chemistry and analytical groups

About You:

  • You hold a PhD in Chemistry, Biochemistry, Biotechnology or related field with experience (PhD 3 or more yrs) in an industrial setting including hands-on laboratory experience in Oligonucleotide fields.

  • Ideally you have strong knowledge of oligonucleotides chemistry and firsthand experience with solid-phase oligonucleotide synthesis using instrumentations like OP100/Oligosynt/AKTA purifiers etc. Having small molecule synthetic organic chemistry experience is a plus.

  • Have previous knowledge or willing to learn oligonucleotide process development (cGMP).

  • Experience with oligonucleotide identification/analysis methods (HPLC) is a plus.

  • Experiences in all other standard laboratory techniques and analytical instrumentation (spectroscopic methods etc.).

  • Highly organized individual, detail-oriented, and a self-starter who continuously seeks to improve the status quo.

  • Effective verbal and written communication skills are required.

  • Candidates with less experience are welcome to apply, however, the position title will be adjusted accordingly.

Meet your future team:

The Small Molecule Process Sciences Team (oligonucleotides, lipids and other small molecule entities) is a highly motivated and active group, with an innate curiosity to learn. You will be reporting to principal scientist, technical operations of Nucleic Acid Therapeutics Development and Manufacturing (NTDM). The team focuses on various activities with Technical Operations (CMC), including sgRNA and lipid manufacturing support, internal process development and tech transfer. The team interfaces cross-functionally via project teams and working groups and is embedded within the larger NTDM group (mRNA, LNP, sgRNA and SM).

#LI-KO2

Covid-19 Vaccination Policy:All Intellia employees, regardless of work location, are expected to follow all applicable federal, state, and local public health regulations and guidelines, and are strongly encouraged to follow all public health recommendations, including being vaccinated for COVID-19.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert